Liver Cancer Therapeutics Market

Global Liver Cancer Therapeutics Market Size (2022 to 2027)

The global liver cancer therapeutics market size is forecasted to grow to USD 1148 million by 2027 from USD 743 million in 2022, registering a CAGR of 9.1% during the forecast period.

Liver cancer signifies the fifth most generally arising cancer and the third foremost reason for deaths associated with cancer globally. Hence, the liver cancer diagnosis and medication market are projected to become an active ground for competition in the coming few years. Several new-targeted therapies are predicted to arrive in the liver cancer therapeutics market shortly. Directed cancer therapies practice medication to avoid the growth of cancer cells by intruding specific molecules, known as molecular targets, thus preventing the movement and development of cancer cells. The treatment procedures mainly focus on cellular and molecular variations affecting cancer cells.

MARKET DRIVERS:

The growing aging population, unmet requirements for liver cancer treatment, drug inventions concerning cancer, increasing government initiatives, rising cancer occurrences, and growing healthcare expenditure propel the global liver cancer therapeutics market.

According to Globocan, approximately 1.2 million new liver cancer cases have been reported worldwide. The increasingly intense research and development activities opposing dangerous diseases have developed in the launch of new drugs and rising FDA approvals for treating hepatocellular carcinoma accounting for 90% of liver cancer. Factors such as alcohol consumption, smoking, and increasing urbanization for liver cancer majorly led to liver cancer. The rising government support and investments made by international healthcare organizations positively reflect the global liver cancer therapeutics market. A wide range of treatment options for liver cancer may soon uplift the demand levels.

MARKET RESTRAINTS:

However, factors such as stringent regulatory processes, high capital investments, the low success rate in clinical trials for drugs, and low approachability in remote areas hinder the global liver cancer therapeutics market growth. 

Impact of COVID-19 on the global liver cancer therapeutics market:

COVID-19 has created an adverse impact on the liver cancer therapeutics market. The pharmaceutical companies are adopting plans to maintain the balance between the supply chain and demand, increasing the products' sales during the COVID-19 emergency. Healthcare organizations have imposed strict guidelines for managing hepatocellular carcinoma patients amid the COVID-19 crisis. The studies have stated that patients with HCC are at high risk of contracting the infection. Therefore, patients are considered in the emergency category during the crisis period.

REPORT COVERAGE:

This research report on the global liver cancer therapeutics market has been segmented and sub-segmented based on type, therapeutics, end-users, and region.

Liver Cancer Therapeutics Market - By Type:      

• Primary    
• Secondary             
• Benign Liver growths         

Based on the type, the secondary segment dominated the market in 2021 and is estimated to continue the dominating trend during the forecast period. Secondary liver cancer is also known as metastatic liver cancer.

Liver Cancer Therapeutics Market - By Therapeutics:

• Hepatocellular Carcinoma
• Cholangio carcinoma        
• Hepatoblastoma  
• Targeted Therapy

Based on therapeutics, the hepatocellular carcinoma segment is the most significant therapeutics type due to its high prevalence of liver cancer. According to the National Organization for Rare Diseases (NORD), there are nearly six new cases of HCC per every 100,000 people in the general population of the U.S. In addition, the high occurrence of cancer and high unemployed medical needs drives the market growth during the analysis period.

The targeted therapy is expected to grow at the highest pace. The segment mainly involves tyrosine inhibitors, limiting the several kinase proteins that accelerate cancer cell growth.

Liver Cancer Therapeutics Market - By End-Users:

• Pediatrics
• Adults    

The adult end-user segment is expected to lead the global liver cancer therapeutics market during the forecast period due to high alcohol consumption and tobacco intake.

Liver Cancer Therapeutics Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America is the largest market for liver cancer therapeutics, followed by Europe and Asia. The growth of the North American market is majorly driven by the factors such as the appearance of better healthcare infrastructure and the increasing aged population. The United States is leading the North American market due to the Y-O-Y increase in liver cancer cases and the growing demand for treatment. As per the American Society of Clinical Oncology, around 42,220 adults have been diagnosed with liver cancer in the U.S. as of 2018. In addition, the early adoption of advanced technology diagnosis products and liver cancer methods makes the region grow more robust. The Canadian liver cancer therapeutics market is next to the U.S. in leading the market. The market players focus more on research and development activities to develop new treatments for liver cancer.

The European market was the second-largest regional global market in 2021. The European market is mainly growing due to rising investments in developing effective therapeutic drugs. Moreover, the targeted drug therapy products lead the market forward. U.K. and Germany are leading economies of the European market. The U.K. is leading the market and will dominate throughout the forecast period. According to the Cancer Research Organization, around 5,736 liver cancer cases were reported in the U.K. in 2015. The liver cancer therapeutics market in Germany and France is observed to grow at the highest CAGR pace. 

Also, Asia-Pacific signifies the fastest-growing region for the liver cancer therapeutics market, owing to increasing aged populations. In addition, an increasing number of liver cancer cases in Asian countries is further fuelling the market in this region. The rising number of clinical studies regarding the liver disease, including cancer, and the rising number of older adults, are other significant factors contributing to the APAC market growth. China is a promising destination for market players in the industry. The broad base target population and vital unused medical needs support the major push for market growth.

On the other hand, Latin America and, the Middle East & Africa are likely to witness considerable market growth in liver cancer therapeutics. Increasing funds and investments by both public and private organizations in research and development in treating cancer.

KEY MARKET PARTICIPANTS:

Some of the significant contributors in the global liver cancer therapeutics market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.